The contribution of genetic predisposition to pediatric cancer: a study integrating extensive phenotyping and state of the art genotyping. - PrediCT - Predispostion to Childhood Tumors

Prinses Máxima Centrum voor Kinderoncologie0 个研究点目标入组 843 人开始时间: 待定最近更新: 2024年6月18日

试验速览

暂无简介。

•Inclusion criteria for the main study PrediCT:
•- Children (age < 19 years) newly diagnosed with cancer or neoplasms at the
•Princess Máxima Center (in a period
•of three years)
•- Written informed consent (by patient when aged 16 years or older, by patient
•and parent(s) when aged 12-16
•years, by parent(s) when younger than 12 years)
•Additional inclusion criteria for REFLECT:
•- Consent for participation in PrediCT
•- Written informed consent for REFLECT. This can include:
•Parents (of children 0-19 years)
•Children aged 12-16 years (additional consent by their parents needed)
•Children aged 16-19 years.
•Additional inclusion criteria for the Hemato add-on study:
•- Consent for participation in PrediCT
•- Children (age < 19 years) diagnosed with hematological malignancies
•(including myelodysplastic syndromes) at the Princess Máxima Center
•- Written informed consent for the Hemato add-on study (by patient when aged 16
•years or older, by patient and parent(s) when aged 12-16 years, by parent(s)
•when younger than 12 years).

发起方

Prinses Máxima Centrum voor Kinderoncologie